Nula Therapeutics

Nula Therapeutics is a San Diego-based biotechnology company focused on the discovery and development of molecular glue degraders. The company's platform is designed to identify small molecules that can induce or stabilize interactions between E3 ubiquitin ligases and target proteins, enabling the degradation of previously undruggable disease-causing proteins. Co-founded by chemical biology pioneers Benjamin Cravatt and Dan Nomura, Nula aims to expand the therapeutic potential of targeted protein degradation beyond traditional heterobifunctional degraders. The company leverages a proprietary discovery platform to identify these glues with high specificity and potency for a variety of therapeutic applications. Nula is backed by prominent venture capital firms, including ARCH Venture Partners and F-Prime Capital, and is currently in the pre-clinical stage of development. Its initial research efforts are primarily focused on addressing high-value targets in oncology and immunology.